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Supplementary Fig. 1. WT and Nf1+/- mice were treated between 4-6 weeks of age with either OVA 
or HDM (experimental asthma) or PBS (controls). Representative (a) H&E and (b) PAS-stained 
images of the lungs from WT and Nf1+/- mice treated with PBS (n=6), HDM (n=6) and OVA (n=6). 
Increased airway wall thickening and immune cell infiltration into bronchial and peri-bronchial sites 
were observed 7 days after OVA and HDM treatment. Boxes indicate thickened bronchial walls. 
Small scale bar, 500 mm; large scale bar, 250 mm. (c) Similar increases in serum IgE were observed 
in WT (n=4) and Nf1+/- (n=4) mice treated with OVA and HDM relative to PBS-treated control mice. 
Data are presented as the mean ± SEM. One-way ANOVA with Bonferroni post-test correction; n.s., 
not significant; Exact P values are indicated within each panel. From left to right in each panel: (c) ns, 
ns, ns, P<0.0001. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Fig. 2. (a) Representative images of murine optic nerves from PBS-, OVA-, and 
HDM-treated Nf1OPG mice. The black lines represent the diameters used to generate the optic nerve 
volumes. (b) Optic nerve volumes from Nf1+/- (n=8) and Nf1OPG mice (n=13) compared to WT 
controls (n=6). Bar graphs represent the means ± SEM of independent biological samples. (c) 
Thickened optic nerves were observed in Nf1+/- mice by MnCl2-enhanced T1-weighted magnetic 
resonance imaging and area measurements. Bar graphs represent the means ± SEM of WT, n = 3, 
Nf1+/-, n = 3, Nf1OPG, n = 3, independent biological samples.  Red arrows point to the optic nerves. (d) 
Thickened optic nerves were also seen on T2-weighted axial magnetic resonance images from 
representative individuals with NF1, but without an OPG (middle panel), relative to those with an 
OPG (right panel) or an individual without NF1 (left panel). Red arrows point to the optic nerves. (e) 
Microglia content (%Iba1+ cells) was increased in the optic nerves of Nf1+/- (n=10) and Nf1OPG (n=8) 
mice relative to WT mice (n=10). Bar graphs represent the means ± SEM of independent biological 
samples. (f) Optic nerve proliferation (%Ki67+ cells) was increased in Nf1OPG mice (n=11) compared 
to Nf1+/- (n=9) and WT mice (n=9). All data are presented as the mean ± SEM. (g) CD3+ T cell content 
was increased in the optic nerves from Nf1OPG (n=8) mice relative to WT (n=10) and Nf1+/- (n=9) 
mice. All data are presented as the mean ± SEM. (h) Graph demonstrating that optic gliomas 
(increased %Ki67+ cells and volumes) form in Nf1OPG (n=13), but not in Nf1+/- (n=8), mice. (i) Graph 
demonstrating that optic gliomas form in Nf1OPG (n=10), but not in Nf1+/- (n=8), mice (increased 
%Ki67+ cells and CD3+ cell content). Graphs demonstrating that (j) OVA (n=8) and HDM (n=8) 
treatments prevent optic glioma formation (12 weeks of age), with %Ki67+ cells and volumes 
comparable to Nf1+/- mice (n=8). (k) Graph demonstrating durable effects of OVA (n=7) and HDM 
(n=8) treatments in Nf1OPG mice at 6 months of age. Scale bars, (a) 100 µm. (d) Scale bars 2cm. One-
way ANOVA with Bonferroni post-test correction; n.s., not significant; Exact P values are indicated 
within each panel. From left to right in each panel: (b) P<0.0001, P=0.0006; (c) P=0.0134, ns, 
P=0.0149; (e) P<0.0001, ns; (f) ns, P<0.0001; (g) ns, P<0.0001. 
 
 
 
 
 
 
 
 
 
Supplementary Fig. 3. (a) Conditioned medium was collected from 2.5 × 106 cells ml−1 mouse 
splenic CD3+ T cells seeded in complete RPMI 1640 medium following 2 days of CD3/CD28 
stimulation (activated; act-Tm) or vehicle (PBS) treatment (non-activated; non-act-Tm). Higher Ccl5 
levels were detected in act-Tm, relative to non-act-Tm, by ELISA (n=4). Nf1OPG mouse optic nerves 
(n=4) have higher RNA expression of (b) Ccl4 and (c) Ccl5 at 12 weeks and 24 weeks (d-e) relative 
to WT mice. (f) No change in Ccl4 RNA expression in the optic nerves from OVA-treated Nf1OPG 
mice was observed relative to PBS-treated Nf1OPG mice at 24 weeks of age by qRT-PCR (n=3). (g) 
Ccl5 expression was reduced relative to PBS-treated Nf1OPG mice by qRT-PCR (n=3). OVA- and 
PBS-treated Nf1OPG mouse optic nerves (n=4) have similar expression of M1 markers [(h) Il1β, (i) Il6, 
(j) Tnfα] and M2 markers [(k) Il4, (l) Il10]. All data are presented as the mean ± SEM. A two-tailed 
Student’s t-test was used. P values are indicated within each panel. From left to right in each panel: 
(a) P<0.0001; (b) P<0.0001; (c) P<0.0001; (d) P<0.0001; (e) P<0.0001; (f) ns; (g) P=0.0217; (h) ns; 
(i) ns; (j) ns; (k) ns; (l) ns. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Fig. 4. (a) Conditioned medium was collected from 2.5 × 106 cells ml−1 PBS- and 
OVA treated mouse splenic CD3+ T cells (n=4) seeded in complete RPMI 1640 medium following 2 
days of CD3/CD28 stimulation (activated; act-Tm) or vehicle (PBS) treatment (non-activated; non-
act-Tm). (b) Similar increases in Ccl4 were detected in the conditioned medium from PBS- and OVA-
treated act-Tm by ELISA (n=4). A one-way ANOVA with Bonferroni post-test correction was used. 
(c) Midkine (100ηg/ml) treatment of WT and Nf1+/- microglia (n=4) for 48 h does not increase Ccl5 
production. (d) Increased CD8+ T cell content was observed in the optic nerves from Nf1OPG relative to 
WT mice. Similar CD4+ T cell content was observed in Nf1OPG and WT optic nerves. Black arrows 
denote representative immunopositive cells (n=5). (e) No Foxp3+ cells were detected in the optic 
nerves from 12-week-old Nf1OPG mice treated with PBS, OVA or HDM. (f) WT microglia were 
treated with either TGFβ (5ηg/ml) alone or in combination with Ccl4 (6000pg/ml). TGFβ does not 
induce microglia Ccl5 production, either alone or in combination with Ccl4 (n=5). One-way ANOVA 
with Bonferroni post-test correction was used. (g-i) Il3, Il4 and Il5 gene expression was examined in 
PBS- and OVA-treated Nf1OPG optic nerves (n=3), and only Il3 expression was higher in OVA-treated 
Nf1OPG mice. A two-tailed Student’s t-test was used. (j-k) WT T cell (n=3) and microglia (n=3) were 
treated with IL-3 (1 ng/mL). No change in T cell Ccl4 or microglia Ccl5 production was observed 
following treatment with IL-3. A two-tailed Student’s t-test was used. (l) 12-week-old Nf1OPG optic 
nerves (n=5) following PBS, OVA, and HDM treatment were co-labelled with Iba1 and Tmem119 
antibodies. Nearly all of the Iba1+ cells were Tmem119+ microglia, rather than Tmem119-negative 
macrophages. (m) Mouse splenic macrophages failed to induce Ccl5 expression in response to Ccl4. 
OVA treatment of mice does not change microglia (n) phagocytosis or (o) viability (n=4, 
66.88±4.09% phagocytic cells). Scale bar, 25µm. A one-way ANOVA with Bonferroni post-test 
correction was used. Exact P values are indicated within each panel. N.S.; not significant. From left to 
right in each panel: (a) P<0.0001, P<0.0001; (b) P=0.0048; (c) ns, P=0.0124; (d) ns, P=0.0124; (f) ) 
P<0.0001; (g) P=0.0160; (h) ns; (i) ns; (j) ns; (k) ns; (m) ns; (n) ns; (o) ns.  
 
 
 
 
 
Supplementary Fig. 5. (a) PCA plot generated from PBS- and OVA-treated CD3+ T cell RNA 
sequencing data (n=5). (b) List of differentially expressed genes, with log-fold changes ≥5 in T cells 
from OVA-, relative to PBS-treated, Nf1OPG mice. All data are presented as the mean ± SEM. 
Increased Dcn RNA expression was detected in CD3+ T cells from the spleen (c-e), cervical lymph 
nodes (f-h) and optic nerve (i-k) of Nf1OPG mice treated with OVA and HDM from 4 to 6 weeks of 
age and harvested at (c, d, f, g, i, j) 12 and (e, h, k) 24 weeks of age (n=3). A two-tailed Student’s t-
test was used. P values are indicated within each panel. From left to right in each panel: (c) P=0.0107; 
(d) P=0.0007; (e) P=0.0033; (f) P=0.0125; (g) P=0.0304, (h) P=0.0020; (i) P=0.0136; (j) P=0.0010; 
(k) P=0.0030.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Fig. 6. (a) OVA-treated Nf1OPG optic nerves do not harbor increased biglycan (Bgn) 
RNA expression (n=5). (b) WT microglia were treated with either biglycan (25 µg/ml) alone or in 
combination with Ccl4 (6000pg/ml). Biglycan alone or in combination with Ccl4 does not induce 
microglia Ccl5 production (n=5). (c) Decorin inhibits increased microglia Ccl5 production in response 
to Ccl4 treatment in vitro (n=4). (d) NFkB inhibition (CAPE) blocks microglia Ccl5 production in 
response to Ccl4 treatment in vitro (n=4). (e) NFB inhibition (CAPE) had no effect on microglia 
viability, as measured using a WST-1 cell viability assay (n=4). A one-way ANOVA with Bonferroni 
post-test correction was used. A two-tailed Student’s t-test was used. (a-e) All data are presented as the 
mean ± SEM. From left to right in each panel: (a) ns; (b) P<0.0001, ns; (c) P<0.0001, P<0.0001; (d) 
P<0.0001, P<0.0001; (e) ns.  
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Supplementary Table 1. Antibodies used. 
Antibody Host Source Dilution 
β-Actin (WB) mouse Cell Signaling, 58169S 1:1000 
CD3 (IHC) rat Abcam, 11089 1:50 
CD4 (IHC) goat R&D systems, AF554-SP 1:50 
CD8α (IHC) rabbit Cell Signaling, 98941S 1:500 
FOXP3 (IHC) rabbit Thermo scientific, 700914 1:100 
HDAC1 mouse Cell Signaling, 5356S 1:1000 
Iba1 (IHC/IF) rabbit Wako, 019-19741 1:500 
IκBα (WB) rabbit Cell Signaling, 4812S 1:1000 
Phospho-IκBα (WB) rabbit Cell Signaling, 2859S 1:1000 
Ki67 (IHC) mouse BD Pharmingen,550609 1:400 
NFκB p65 rabbit Cell Signaling, 8242S 1:1000 
Phospho-NFκB p65 rabbit Cell Signaling, 3033S 1:1000 
TMEM119 (IF) rabbit Abcam, 209064 1:500 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 2. qRT-PCR probes used. 
Gene Probe set 
Bgn 
(mouse) 
Mm01191753_m1(TaqMan Gene Expression) 
Ccl4 
(mouse) 
Mm00443111_m1(TaqMan Gene Expression) 
Ccl5 
(mouse) 
Mm01302427_m1(TaqMan Gene Expression) 
Dcn 
(mouse) 
Mm00442039_m1(TaqMan Gene Expression) 
Gapdh 
(mouse) 
Mm99999915_g1 (TaqMan Gene Expression); internal control 
Il1β 
(mouse) 
Mm00434228_m1(TaqMan Gene Expression) 
Il3 
(mouse) 
Mm00439631_m1(TaqMan Gene Expression) 
Il4 
(mouse) 
Mm00445259_m1(TaqMan Gene Expression) 
Il5 
(mouse) 
Mm00439646_m1(TaqMan Gene Expression) 
Il6 
(mouse) 
Mm00446190_m1(TaqMan Gene Expression) 
Il10 
(mouse) 
Mm01288386_m1(TaqMan Gene Expression) 
Tnfα 
(mouse) 
Mm00443258_m1(TaqMan Gene Expression) 
 
